Amgen Issues Statement in Response to Revised ESA Labeling Received from the FDA Today
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 30, 2008--Amgen
(NASDAQ: AMGN) issued the following statement in response to the
receipt today of the complete response on the revised ESA labeling
from the FDA.
"This label is consistent with our expectations. We will soon be
communicating the revised product labeling for ESAs to both physicians
The potential impact of this revised label was factored into our
updated guidance announced July 28, 2008.
CONTACT: Amgen, Thousand Oaks
Trish Hawkins, 805-447-5631 (media)
Arvind Sood, 805-447-1060 (investors)